Triazibe-Based Tripod Linker System for Drug Delivery and Diagnosis

Background:

Combination therapy is the primary treatment option against cancer, because multiple agents in combination, synergistically improve efficacy and are less prone to resistance due to their distinct action mechanisms. Despite these advantages, lack of tumor specificity continues to be a serious issue in combination therapy, thus resulting in a need to develop an efficient vehicle for targeted drug delivery.

Technology Overview:

Researchers at Stony Brook University have invented a robust tumor targeted drug delivery system (TTDDS) that consist of (a) triazine based tripod splitter module (b) two-drug payload feature (c) self immolative disulfide linkers for drug release, and (d) PEG linkers to improve solubility. Using biotin as a tumor targeting moiety and taxoid-camptothecin combination in the TTDDS, the in vitro data demonstrates a twofold improvement in selectivity and a cooperative effect in efficacy. Further Details: Vineberg et al., J. Med. Chem. 2014; 57, 5777-91 Vineberg et al., J. Med. Chem. 2015; 58, 2406-16 Seitz et al., Bioorg. Med. Chem., 2015; 23, 2187-94

Advantages:

Applicable to a variety of two drug combinations Amenable to fluorescent coupling and PET, SPECT, and MRI imaging Deliver two different drugs to a tumor

Applications:

Tumor-targeting drug delivery and diagnosis

Intellectual Property Summary:

Patent application submitted

Stage of Development:

US Utility Pending (# 15/127,083)

Licensing Status:

Available for License. Stony Brook University seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Potential:

Licensing

Additional Information: